Back to top
more

Ironwood Pharmaceuticals (IRWD)

(Delayed Data from NSDQ)

$4.19 USD

4.19
1,066,402

+0.24 (6.08%)

Updated Nov 1, 2024 03:59 PM ET

After-Market: $4.19 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Implied Volatility Surging for Ironwood (IRWD) Stock Options

Investors need to pay close attention to Ironwood (IRWD) stock based on the movements in the options market lately.

Ironwood (IRWD) Q2 Earnings & Revenues Fall Shy of Estimates

Ironwood (IRWD) reports breakeven earnings for second-quarter 2024. Revenues miss estimates. The company lowers revenue guidance for 2024. Stock falls.

Ironwood Pharmaceuticals (IRWD) Reports Break-Even Earnings for Q2

Ironwood (IRWD) delivered earnings and revenue surprises of -100% and 9.08%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Heron Therapeutics (HRTX) Reports Q2 Loss, Tops Revenue Estimates

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -50% and 1.91%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Ironwood Pharmaceuticals (IRWD) Q2 Earnings Expected to Decline

Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

New Strong Sell Stocks for July 23rd

ALK, DINO and IRWD have been added to the Zacks Rank #5 (Strong Sell) List on July 23, 2024.

Implied Volatility Surging for Ironwood Pharmaceuticals (IRWD) Stock Options

Investors need to pay close attention to Ironwood Pharmaceuticals (IRWD) stock based on the movements in the options market lately.

New Strong Sell Stocks for July 5th

ARCO, IRWD and AVT have been added to the Zacks Rank #5 (Strong Sell) List on July 5, 2024.

Ironwood (IRWD) Q1 Earnings & Revenues Fall Shy of Estimates

Ironwood (IRWD) incurs loss in the first quarter of 2024. Revenues decline year over year and miss estimates. The company lowers revenue guidance for 2024. Stock falls.

Earnings Preview: Ironwood Pharmaceuticals (IRWD) Q1 Earnings Expected to Decline

Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

OPKO Health (OPK) And Entera Bio Announce Data for GLP-2

OPKO Health (OPK) and Entera Bio announce robust pharmacokinetic results for the proprietary GLP-2 agonist developed by OPK Heath.

Ironwood (IRWD) Q4 Earnings Miss, Revenues Beat Marginally

Ironwood's (IRWD) fourth-quarter 2023 earnings lag estimates while revenues beat the same marginally. Linzess collaboration revenues drive the top line.

Ironwood Pharmaceuticals (IRWD) Reports Break-Even Earnings for Q4

Ironwood (IRWD) delivered earnings and revenue surprises of -100% and 0.84%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Ironwood (IRWD) is on the Move, Here's Why the Trend Could be Sustainable

If you are looking for stocks that are well positioned to maintain their recent uptrend, Ironwood (IRWD) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Wall Street Analysts Think Ironwood (IRWD) Could Surge 37.6%: Read This Before Placing a Bet

The consensus price target hints at a 37.6% upside potential for Ironwood (IRWD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Ironwood's (IRWD) Q3 Earnings Miss Mark, Linzess Volume Rises

Ironwood's (IRWD) third-quarter 2023 earnings miss estimates, while revenues beat the same. Linzess collaboration revenues drive the top line.

Ironwood (IRWD) Surges 7.6%: Is This an Indication of Further Gains?

Ironwood (IRWD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Implied Volatility Surging for Ironwood (IRWD) Stock Options

Investors need to pay close attention to Ironwood (IRWD) stock based on the movements in the options market lately.

Why Is Ironwood (IRWD) Down 9.6% Since Last Earnings Report?

Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ironwood's (IRWD) Reports Q2 Loss, Linzess Volume Rises

Ironwood (IRWD) reports loss for second-quarter 2023. The top line increases year over year, driven by growth in Linzess collaboration revenues.

Ironwood Pharmaceuticals (IRWD) Q2 Earnings and Revenues Surpass Estimates

Ironwood (IRWD) delivered earnings and revenue surprises of 24% and 3.79%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Biotech Stock Roundup: KDNY Up on NVS Buyout, BIIB & Eisai's AD Drug Update & More

Acquisition and regulatory updates from Chinook Therapeutics (KDNY) and Biogen (BIIB) are in focus in the biotech sector.

Ironwood (IRWD), AbbVie Get FDA Nod for Linzess Label Expansion

Ironwood (IRWD) lead drug Linzess gets FDA approval for pediatric functional constipation The label expansion of the drug is expected to boost the company's sales.

Biotech Stock Roundup: IRWD Announces Buyout, ICPT, SRPT & PTCT Fall on Updates

Regulatory and pipeline updates from Intercept (ICPT) and Sarepta (SRPT) lead to a decline in the share price of both companies.

Ironwood (IRWD) to Acquire VectivBio for $1B, Stock Up 3.6%

Ironwood (IRWD) offers to acquire VectivBio, which will help strengthen its gastrointestinal treatment portfolio.